Lenvatinib/pembrolizumab has good activity in advanced RCC, other solid tumorsJanuary 31, 2020Renal Cell CarcinomaImmuno-oncologyGenitourinary CancerMelanomaLung CancerGynecologic CancerHead & Neck/Thyroid Cancers
Dual immunotherapy goes the distance in MSI-H colorectal cancerJanuary 29, 2020GastroenterologyImmuno-oncologyGastrointestinal Cancer
T-VEC plus pembrolizumab yields promising response rate in phase 2 sarcoma studyJanuary 24, 2020Sarcoma & GISTImmuno-oncology
Experts break down latest CAR T-cell advances in lymphomaJanuary 22, 2020Immuno-oncologyImmunotherapyLymphoma & Plasma Cell Disorders
CAR T cells produce complete responses in T-cell malignanciesJanuary 7, 2020Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersImmunotherapyImmuno-oncology
CAR T-cell therapy advances in CLLDecember 26, 2019Leukemia, Myelodysplasia, TransplantationImmuno-oncologyImmunotherapy
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patientsDecember 23, 2019ImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncology
Survival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019Lymphoma & Plasma Cell DisordersDLBCLFollicular LymphomaImmuno-oncologyImmunotherapy
‘Real-world’ data show CAR T therapies are cost effectiveDecember 13, 2019Immuno-oncologyImmunotherapyPractice Management
An off-the-shelf drug to rival CAR T cells: ‘very exciting’December 13, 2019Lymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Bispecific CAR T-cells yield high response rate in relapsed/refractory myelomaDecember 7, 2019Immuno-oncologyImmunotherapyLymphoma & Plasma Cell Disorders
High complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Immuno-oncologyImmunotherapyLymphoma & Plasma Cell DisordersRare Diseases
Patient-reported outcomes support first-line pembrolizumab for NSCLCDecember 6, 2019Lung CancerImmuno-oncology
